Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Leuko
AddedFeb 15, 2024
UpdatedJun 18, 2026
Leuko

Leuko

Series A

Leuko: Innovating non-invasive white blood cell devices for global health management.

HQ
Boston, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Leuko was founded with the mission to revolutionize health management through non-invasive medical devices. The company focuses on developing innovative solutions for white blood cell (WBC) monitoring, crucial for patients undergoing chemotherapy and those at risk of life-threatening infections. Their flagship product, PointCheck™, is a fast, portable, and user-friendly device that allows frequent WBC assessments without the need for blood draws, aiming to enhance the quality of life and clinical outcomes for immunosuppressed patients worldwide.

Leuko has attracted notable attention from investors and healthcare professionals due to its groundbreaking technology. While the device is still investigational and not yet available for sale, it has the potential to significantly impact patient care by enabling more frequent and less invasive monitoring. This innovation positions Leuko as a key player in the medical device industry, with the promise of transforming how white blood cell counts are managed globally.

Leuko - Similar Companies

LeukoDx logo

LeukoDx

Levisonics logo

Levisonics

levisonics.com

Sanguis logo

Sanguis

sanguiswine.com

Chemeleon logo

Chemeleon

chemeleon.com

Delee logo

Delee

delee.co

Weavr Health logo

Weavr Health

Cellia Science logo

Cellia Science

celliasci.com

The Blue Box Biomedical Solutions logo

The Blue Box Biomedical Solutions

thebluebox.ai

LEO Innovation Lab logo

LEO Innovation Lab

Nano Mobile Healthcare logo

Nano Mobile Healthcare

Cellens logo

Cellens

cellensinc.com

Lean Med logo

Lean Med

GlucoVista logo

GlucoVista

glucovista.com

Bright Uro logo

Bright Uro

brighturo.com

Luminate Medical logo

Luminate Medical

luminatemed.com

Leuko - Quick Facts

Who are Leuko's competitors?

Companies similar to Leuko include LeukoDx, Levisonics, Sanguis and Chemeleon.

When was Leuko founded?

Leuko was founded in 2014.

Where is Leuko's headquarters located?

Leuko's headquarters is located in Boston, MA, US.

When was Leuko's last funding round?

Leuko's most recent funding round was for $5M (USD) in September 2022.

How much has Leuko raised to-date?

As of Sep 23, 2022, Leuko has raised a total of $7.3M (USD).

How many employees does Leuko have?

Leuko has 15 employees as of Feb 5, 2024.

Leuko - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Consumers
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Biotech
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified